China approves Sinovac Biotech Covid-19 vaccine for general public use | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 11, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 11, 2025
China approves Sinovac Biotech Covid-19 vaccine for general public use

Coronavirus chronicle

Reuters
06 February, 2021, 03:35 pm
Last modified: 06 February, 2021, 03:41 pm

Related News

  • Rubio to meet China's foreign minister in Malaysia as US-Chinese tensions mount
  • China, Canada commit to deeper engagement with Bangladesh on trade, humanitarian assistance
  • Tariffs drive US clothing imports from China to 22-year low in May
  • Chinese investors want better infrastructure in Bangladesh to boost joint ventures
  • Beijing seeks to fast-track investment treaty with Dhaka, no matter who leads: Ambassador Yao

China approves Sinovac Biotech Covid-19 vaccine for general public use

It marks the second Covid-19 vaccine green-lighted for public use in China

Reuters
06 February, 2021, 03:35 pm
Last modified: 06 February, 2021, 03:41 pm
FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo
FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo

Sinovac Biotech said on Saturday that its unit's Covid-19 vaccine has been formally approved for use by the general public by China's medical products regulator.

It marks the second Covid-19 vaccine green-lighted for public use in China, after a shot developed by a Beijing institute affiliated to state-owned China National Pharmaceutical Group (Sinopharm) was approved in December.

Prior to the approvals, both vaccines have already been used in China's vaccination program mainly targeting key groups deemed to be at higher risk of exposure to the virus.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have granted emergency authorizations for the CoronaVac vaccine developed by Sinovac Life Sciences, Sinovac said in a news release.

The approval is based on the two-month results from late-stage clinical trials overseas, from which the final analysis data has not yet been obtained, Sinovac said.

China / Sinovac / COVID-19 / Vaccine / approve / general use

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • How tender rules and a lone bidder stall a $2.5b power plant
    How tender rules and a lone bidder stall a $2.5b power plant
  • Bangladesh and US hold tariff talks for second day on 9July 2025. Photo: CA Press Wing
    35% tariff: Bangladesh, US 'reach general consensus on some issues' on second day of talks; final round today
  • BNP senior leader Salahuddin Ahmed. Photo: Collected
    No scope for electoral alliance with Jamaat, door not closed for NCP: BNP's Salahuddin

MOST VIEWED

  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • In terms of stream of education, girls maintained their excellence as well. Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
    Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
  • Students sit for SSC exam at Motijheel Girls' High School on 10 April 2025. Photo: Mehedi Hasan/TBS
    SSC exam results out: Here's how you can check online and via SMS
  • The overall pass rate across all boards this year, 68.45%, is significantly lower than last year's. Photo: Focus Bangla
    SSC 2025: Rajshahi board records highest pass rate, Barishal lowest
  • Representational image. Photo: Collected
    35% tariff: Bangladesh, US 'agree on most issues' as first day of talks ends

Related News

  • Rubio to meet China's foreign minister in Malaysia as US-Chinese tensions mount
  • China, Canada commit to deeper engagement with Bangladesh on trade, humanitarian assistance
  • Tariffs drive US clothing imports from China to 22-year low in May
  • Chinese investors want better infrastructure in Bangladesh to boost joint ventures
  • Beijing seeks to fast-track investment treaty with Dhaka, no matter who leads: Ambassador Yao

Features

Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

17h | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

20h | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

20h | Panorama
Photo: Rajib Dhar/TBS

11 July 2024: Riot vehicles, water cannons hit the streets as police crack down on protesters

13h | Panorama

More Videos from TBS

India is strengthening ties with Israel

India is strengthening ties with Israel

11m | TBS World
'Hypocrisy' will not continue, Iran tells IAEA

'Hypocrisy' will not continue, Iran tells IAEA

16h | TBS World
OpenAI to release web browser in challenge to Google Chrome

OpenAI to release web browser in challenge to Google Chrome

16h | TBS World
Will the title 'Honorable and Excellency' be abolished?

Will the title 'Honorable and Excellency' be abolished?

17h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net